Madison Avenue Entities Disclose 4.19M Shares, 9.1% of CARGO Therapeutics
Rhea-AI Filing Summary
CARGO Therapeutics, Inc. Schedule 13G/A discloses that a group of affiliated investment entities led by Madison Avenue International LP and related parties beneficially own 4,193,626 shares of common stock, representing approximately 9.1% of the company's outstanding common stock based on 46,110,228 shares outstanding as of April 21, 2025. The ownership is reported as shared voting and shared dispositive power rather than sole control.
The filing identifies the reporting persons (Madison Avenue International LP; Madison Avenue Partners, LP; EMAI Management, LLC; Madison Avenue GP, LLC; Caraway Jackson Investments LLC; and Eli Samaha) and states the holdings are not intended to influence or change control of the issuer, consistent with a passive Schedule 13G filing.
Positive
- Material disclosure: Reporting persons beneficially own 4,193,626 shares, ~9.1% of common stock, a clearly reported >5% position.
- Passive intent certified: Item 10 states the securities were not acquired to change or influence control, consistent with a Schedule 13G filing.
- Complete ownership chain disclosed: The filing identifies the investment entities and the individual (Eli Samaha) connected to the holdings, improving transparency.
Negative
- No sole voting or dispositive power: The reporting persons disclose 0 shares of sole voting or sole dispositive power, indicating they do not control votes or dispositions individually.
Insights
TL;DR: Madison Avenue group holds a material 9.1% passive stake (4,193,626 shares) in CRGX, reported with shared voting and dispositive power.
This Schedule 13G/A reports a >5% position, which is material for investor ownership tables and can affect perceived shareholder concentration. The filing documents the ownership chain across fund entities and an individual (Eli Samaha) and explicitly reports 0 shares of sole voting or dispositive power and 4,193,626 shares of shared power. The statement in Item 10 certifies the stake is not held to change or influence control, aligning with standard passive investor treatment under Rule 13d-1(b).
TL;DR: The submission discloses a coordinated group structure owning 9.1% of CRGX with only shared voting/dispositive authority and a passive intent certification.
The report identifies multiple related legal entities and an individual manager, indicating centralized oversight of the position while maintaining a passive posture. The absence of sole voting or dispositive power is explicit and relevant for governance: board-control risk is limited per the filing. The filing references prior Schedule 13G exhibits for group membership details, and the beneficial ownership basis is tied to the issuer's reported outstanding shares of 46,110,228.